Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Adakveo Coverage & Prior Auth Update | O…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 212.0

    Adakveo (crizanlizumab-tmca) coverage

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 212.0 alerts

    Get alerted when Policy MBP 212.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization criteria for Adakveo (crizanlizumab-tmca) for members of Geisinger Health Plan across applicable lines of business (Commercial, Medicare, CHIP).

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAdakveo (crizanlizumab-tmca) coverage
    Policy CodePolicy MBP 212.0
    Change TypeLine-of-business table revision (Medicaid removed)
    Effective Date
    Last ReviewApr 22, 2025
    Next Review Date
    Key ActionObtain prior authorization from the Medical Director or designee; authorization duration is 12 months with annual re-review.
    SourceLink
    POLICY UPDATE CHANGES

    LOB table, taglines, removed Medicaid business segment.

    >=16minimum member age for coverage
    3 monthshydroxyurea trial required
    12 monthsauthorization duration
    requiredVOC documentation
    commercial, Medicare, CHIP
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAdakveo (crizanlizumab-tmca) coverage
    Policy CodePolicy MBP 212.0
    Change TypeLine-of-business table revision (Medicaid removed)
    Effective Date
    Last ReviewApr 22, 2025
    Next Review Date
    Key ActionObtain prior authorization from the Medical Director or designee; authorization duration is 12 months with annual re-review.
    SourceLink
    On This Page
    Coverage Criteria for Adakveo (crizanlizumab-tmca)Key Clinical & Coding ParametersProvider Requirements, Prior Authorization, and DocumentationDefinitions and Policy TermsBackgroundPolicy Revision History

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    lines of business

    Coverage Criteria for Adakveo (crizanlizumab-tmca)

    Initial therapy criteria (by line of business)

    Covered when ALL of the following are met

    Commercial and CHIP initial approval: Prescription written by or in consultation with a hematologist; member >= 16 years; diagnosis of sickle cell disease; documentation of number of vaso-occlusive crises in the previous 12 months; documentation of intolerance to, contraindication to, or therapeutic failure on a minimum 3-month trial of generic hydroxyurea; documentation of therapeutic failure on, intolerance to, or contraindication to Endarinone

    Authorization duration 12 months; reauthorization requires medical record documentation of continued or sustained improvement in acute complications (number of VOCs, hospitalizations, ACS occurrences).

    Medicare initial approval: Prescription written by or in consultation with a hematologist; member >= 16 years; diagnosis of sickle cell disease; documentation of number of vaso-occlusive crises in the previous 12 months; documentation of intolerance to, contraindication to, or therapeutic failure on a minimum 3-month trial of generic hydroxyureanone

    Authorization duration 12 months; reauthorization requires medical record documentation of continued or sustained improvement in acute complications (number of VOCs, hospitalizations, ACS occurrences).

    Eligibility and coverage are subject to the member's specific contract and line of business. Eligibility and contract-specific benefit limitations and/or exclusions will apply, and any coverage statements in the applicable line-of-business benefit document will supersede this policy.

    This policy applies to Geisinger Health Plan members in the listed lines of business (Commercial, Medicare, CHIP) and establishes medical necessity criteria and prior authorization requirements for Adakveo (crizanlizumab-tmca) consistent with those contract terms.

    Key Clinical & Coding Parameters

    Minimum age
    Minimum age for coverage>= 16 years
    Documentation requiredMember age ≥=16 documented in medical record
    Applies to lines of businessCommercial, Medicare, CHIP per criteria sets
    Hydroxyurea trial duration
    Required hydroxyurea trial duration>= 3 months
    Trial must be of generic hydroxyureaMedical record must document a minimum 3-month trial of generic hydroxyurea
    Failure/intolerance/contraindication documented

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; 12-month authorization with annual re-review

    Prior authorization is required for Adakveo; requests are reviewed by the Medical Director or designee. Authorizations are issued for a 12-month treatment period with re-review every 12 months.

    Step Therapy

    Step therapy: ≥3-month trial of generic hydroxyurea (and Endari for commercial/CHIP)

    A minimum 3-month trial of generic hydroxyurea is required prior to approval. Documentation must show intolerance to, contraindication to, or therapeutic failure on that ≥3-month hydroxyurea trial; for commercial and CHIP members, therapeutic failure/intolerance/contraindication to Endari is also required.

    • Document minimum 3-month trial duration of generic hydroxyurea
    • Document intolerance, contraindication, or therapeutic failure on hydroxyurea
    • For commercial and CHIP: document therapeutic failure/intolerance/contraindication to Endari

    Definitions and Policy Terms

    Adakveo (crizanlizumab-tmca)
    Drug class & mechanismHumanized monoclonal antibody that binds to P-selectin and blocks interactions that contribute to vascular occlusion in sickle cell disease
    Clinical effectInhibits interactions among endothelial cells, platelets, red blood cells, and leukocytes to decrease platelet aggregation, maintain blood flow, and reduce sickle cell–related crises
    Indication in policyFramed for reduction of vaso-occlusive crises in patients with sickle cell disease aged ≥16 years
    Medical Necessity
    Definition of Medical NecessityServices that are appropriate for the symptoms and diagnosis or treatment of the member's condition; provided for diagnosis and direct care; in accordance with current standards of good medical treatment; not primarily for convenience; and the most appropriate source or level of service
    Application to hospitalization

    Background

    Adakveo (crizanlizumab-tmca) is a humanized monoclonal antibody that binds to P-selectin, blocking cell adhesion interactions that contribute to vascular occlusion in sickle cell disease. The agent is used to reduce the frequency of sickle cell–related vaso-occlusive crises in patients meeting the clinical criteria described in this policy.

    Use of Adakveo under this policy is focused on patients with sickle cell disease aged >= 16 years who meet the documented clinical requirements (including prior therapies, number of vaso-occlusive crises, and prescriber specialty) and who have received prior authorization as specified.

    Policy Revision History

    2025-04-22material_revisionLatest

    LOB table and taglines updated; Medicaid business segment removed from policy.

    2023-03-22revision

    LOB carve out applied; Medicaid business segment noted in prior revision history.

    2023-12-28reference_update
    Documentation must show intolerance, contraindication, or therapeutic failure on the trial
    Documentation Required

    Required medical record documentation (prescriber, age, diagnosis, VOC history)

    Medical records must document that the prescription was written by or in consultation with a hematologist, the member is ≥16 years old, a diagnosis of sickle cell disease, and the number of vaso‑occlusive crises in the prior 12 months. For reauthorization, document continued or sustained improvement in acute complications (VOCs, hospitalizations, ACS occurrences).

    • Prescriber specialty: written by or in consultation with a hematologist
    • Member age: ≥16 years
    • Diagnosis: sickle cell disease
    • Clinical history: number of vaso‑occlusive crises in prior 12 months
    • For reauthorization: documentation of continued/sustained improvement in VOCs, hospitalizations, and ACS
    Denial Risk

    Denial risk: missing prior authorization or insufficient documentation

    Failure to obtain prior authorization from the Medical Director or designee, or failure to provide the required documentation (age ≥16, sickle cell diagnosis, number of VOCs in prior 12 months, ≥3‑month hydroxyurea trial with intolerance/contraindication/therapeutic failure, and for commercial/CHIP also Endari failure/intolerance/contraindication) may result in denial.

    • Prior authorization must be obtained from the Medical Director or designee before treatment
    • Provide complete documentation of all required elements to avoid denial
    When applied to hospitalization, member requires acute inpatient care due to services or condition and cannot receive safe/adequate care as an outpatient
    Decision contextDetermined by the Plan as Covered Services rendered by a Health Care Provider meeting these criteria

    References added to the policy.

    2020-05-19creation

    Policy devised (initial creation).